DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 200 filers reported holding DENALI THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 9.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $8,076,419 | -69.8% | 350,539 | -63.5% | 0.02% | -71.7% |
| Q4 2022 | $26,715,371 | +28.8% | 960,639 | +42.1% | 0.06% | +33.3% |
| Q3 2022 | $20,744,000 | -13.8% | 675,870 | -17.3% | 0.04% | -10.0% |
| Q2 2022 | $24,063,000 | +389.3% | 817,650 | +434.9% | 0.05% | +455.6% |
| Q1 2022 | $4,918,000 | -71.3% | 152,855 | -60.2% | 0.01% | -71.9% |
| Q4 2021 | $17,123,000 | -36.1% | 383,944 | -27.7% | 0.03% | -71.2% |
| Q3 2021 | $26,808,000 | -47.1% | 531,358 | -17.7% | 0.11% | -51.5% |
| Q2 2021 | $50,672,000 | +791.8% | 645,999 | +549.1% | 0.23% | +780.8% |
| Q1 2021 | $5,682,000 | -51.2% | 99,518 | -69.4% | 0.03% | -65.3% |
| Q3 2020 | $11,651,000 | +1148.8% | 325,168 | +743.1% | 0.08% | +971.4% |
| Q2 2020 | $933,000 | -78.0% | 38,570 | -84.1% | 0.01% | -83.3% |
| Q1 2020 | $4,239,000 | +424.6% | 242,120 | +422.1% | 0.04% | +600.0% |
| Q4 2019 | $808,000 | +12.5% | 46,377 | +49.9% | 0.01% | +100.0% |
| Q1 2019 | $718,000 | – | 30,946 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |